Matches in SemOpenAlex for { <https://semopenalex.org/work/W87448443> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W87448443 abstract "Lenalidomide is currently licensed only for previously treated multiple myeloma (MM) patients in Europe. A phase III trial, comprising 459 patients, evaluated lenalidomide as first-line therapy for transplant-ineligible patients. Within this three-armed trial, lenalidomide induction therapy with melphalan and prednisone followed either by lendalidomide maintenance therapy (MPR-R arm) or by placebo maintenance (MPR) and placebo with melphalan and prednisone followed by placebo maintenance therapy (MP arm) were compared. The primary outcome was progression-free survival (PFS) in the MPR-R group compared to the MP group. Overall, median PFS was 31 months in the MPR-R group, 14 months in the MPR and 13 months in the MP group, yielding a gain of 17 months for the MPR-R group in comparison to the MPR group and of 18 months in comparison to the MP group. Furthermore, complete or partial responses, were superior for the two groups which had received lenalidomide and duration of response was significantly longer for the maintenance lenalidomide group (MPR-R) than for those with placebo maintenance. Higher grade haematologic AEs during induction therapy occurred more often in the lenalidomide groups than in the placebo group; 2% of deaths in the MPR-R group and 1% in the MPR group respectively, were considered as treatment-related but no results were provided for the MP group. Second primary tumours developed in 7% of patients in the two lenalidomide groups in contrast to 3% in the MP group. The increase in PFS was mainly attributable to lenalidomide maintenance therapy, but only about 60% of patients entered this phase. Furthermore, subjects receiving maintenance therapy showed better baseline characteristics than the overall study population. Also, since no commonly accepted criteria for determination of transplant eligibility -besides age- exist (co-morbidities and the biological age are being considered), it remains questionable if the primary inclusion criteria (i.e. ≥65 years, Karnofsky performance score ≥60%, no serious medical condition) actually led to the enrolment of patients who would be deemed transplant-ineligible in clinical practice. In addition, data on both, adverse events -specifically for elderly patients- and quality of life are missing." @default.
- W87448443 created "2016-06-24" @default.
- W87448443 creator A5007087884 @default.
- W87448443 creator A5032291905 @default.
- W87448443 date "2012-09-01" @default.
- W87448443 modified "2023-09-27" @default.
- W87448443 title "Lenalidomide (Revlimid®) for the first-line therapy of transplant-ineligible patients with multiple myeloma" @default.
- W87448443 hasPublicationYear "2012" @default.
- W87448443 type Work @default.
- W87448443 sameAs 87448443 @default.
- W87448443 citedByCount "0" @default.
- W87448443 crossrefType "journal-article" @default.
- W87448443 hasAuthorship W87448443A5007087884 @default.
- W87448443 hasAuthorship W87448443A5032291905 @default.
- W87448443 hasConcept C126322002 @default.
- W87448443 hasConcept C141071460 @default.
- W87448443 hasConcept C142724271 @default.
- W87448443 hasConcept C143998085 @default.
- W87448443 hasConcept C204787440 @default.
- W87448443 hasConcept C27081682 @default.
- W87448443 hasConcept C2776063141 @default.
- W87448443 hasConcept C2776364478 @default.
- W87448443 hasConcept C2776694085 @default.
- W87448443 hasConcept C2778283404 @default.
- W87448443 hasConcept C2778684742 @default.
- W87448443 hasConcept C2778720950 @default.
- W87448443 hasConcept C71924100 @default.
- W87448443 hasConcept C90924648 @default.
- W87448443 hasConceptScore W87448443C126322002 @default.
- W87448443 hasConceptScore W87448443C141071460 @default.
- W87448443 hasConceptScore W87448443C142724271 @default.
- W87448443 hasConceptScore W87448443C143998085 @default.
- W87448443 hasConceptScore W87448443C204787440 @default.
- W87448443 hasConceptScore W87448443C27081682 @default.
- W87448443 hasConceptScore W87448443C2776063141 @default.
- W87448443 hasConceptScore W87448443C2776364478 @default.
- W87448443 hasConceptScore W87448443C2776694085 @default.
- W87448443 hasConceptScore W87448443C2778283404 @default.
- W87448443 hasConceptScore W87448443C2778684742 @default.
- W87448443 hasConceptScore W87448443C2778720950 @default.
- W87448443 hasConceptScore W87448443C71924100 @default.
- W87448443 hasConceptScore W87448443C90924648 @default.
- W87448443 hasLocation W874484431 @default.
- W87448443 hasOpenAccess W87448443 @default.
- W87448443 hasPrimaryLocation W874484431 @default.
- W87448443 hasRelatedWork W2004136640 @default.
- W87448443 hasRelatedWork W2014737912 @default.
- W87448443 hasRelatedWork W2015950109 @default.
- W87448443 hasRelatedWork W2060496777 @default.
- W87448443 hasRelatedWork W2128084036 @default.
- W87448443 hasRelatedWork W2137332900 @default.
- W87448443 hasRelatedWork W2169336006 @default.
- W87448443 hasRelatedWork W2236041786 @default.
- W87448443 hasRelatedWork W2334764571 @default.
- W87448443 hasRelatedWork W2408874427 @default.
- W87448443 hasRelatedWork W2530122702 @default.
- W87448443 hasRelatedWork W2530368080 @default.
- W87448443 hasRelatedWork W2549355039 @default.
- W87448443 hasRelatedWork W2556749292 @default.
- W87448443 hasRelatedWork W2567188480 @default.
- W87448443 hasRelatedWork W2590133597 @default.
- W87448443 hasRelatedWork W2620526750 @default.
- W87448443 hasRelatedWork W2987632797 @default.
- W87448443 hasRelatedWork W3005219607 @default.
- W87448443 hasRelatedWork W3198488816 @default.
- W87448443 isParatext "false" @default.
- W87448443 isRetracted "false" @default.
- W87448443 magId "87448443" @default.
- W87448443 workType "article" @default.